Bayer's Ask Bio unit starts Phase II heart failure gene therapy
The Phase II trial called GenePHIT is the largest adaptive, double-blind, placebo-controlled, randomised, multicentre trial ever to evaluate the...
AZmed closes €15m Series A financing
AZmed said it will use the €15m to boost marketing of its proprietary artificial intelligence (AI) platform Rayvolve worldwide particularly in...
Roche opens €90m gene therapy development centre
Roche sees the €90m investment as a harbinger of the German government's "National Strategy for Gene and Cell Therapies", which has been...
Researcher find potential target for atherosclerosis
Researchers have found a new way to reverse atherosclerotic plaque formation at the early stages. In Nature Cardiovascular Research, Alma...
TME Pharma gets FDA Fast Track for Glioblastoma
TME Pharma N.V. with research sites in France and Germany (listed at Euronext Growth Paris: ALTME) is developing novel therapies for treatment of...
Electrochaea sells biomethane reactor to Again A/S
Like German bio-CH4 producer Electrochea GmbH, Danish Again A/S is using CO2-fxing archaea, but to manufacture carbon-negative chemicals such...
Essential Pharma acquires Renaissance Pharma Ltd
Renaissance Pharma Ltd, which was only founded in September 2023 with the licensing of the anti-GD2 antibody from St Jude Children's Research...